acute and chronic wounds
Conditions
Interventions
Group 1: Deployment of the products of the DracoFoam Infekt line according to routine practice
the decision on the treatment has to be made by the treating physician independently of the consideration of the patient for study participation
patients will only be asked to participate in the study once the decision to carry out the therapy using a product of the DracoFoam Infekt line has been made by the treating physician.
Sponsors
Dr. Ausbüttel & Co. GmbH
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Indication for treatment by antimicrobial wound therapy - Presence of a signed informed consent form (with patient being able to consent) - Age =18 years - Expected ability of the practitioner to provide the patient with regular care as part of routine medical practice
Exclusion criteria
Exclusion criteria: - Incapacity of the patient to consent - Lack of ability of the patient to report any possibly occurring side effects (e.g. in the presence of severe cognitive deficits) - Presence of a terminal disease with a life expectancy of 250cm2 (It is no prerequisite that patients are treatment naïve, when included into the study).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. number of incidents 2. decrease of wound infection/ decrease of signs of infection 3. improvement of the wound situation | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. decrease in pain 2. decrease in wound odour 3. improvement of the appearance of the wound surrounding skin | — |
Countries
Germany
Contacts
Public ContactChristina Pankraz
Dr. Ausbüttel & Co. GmbH
Outcome results
None listed